CAR-T cells, genetically engineered and equipped with specific receptors to target and combat cancer cells, are primarily divided into two categories: autologous and allogenic CAR-T cells. Hereby, autologous CAR-T cells derive from the patient’s own white blood cells and are reintroduced after modification, whereas allogenic CAR-T cells are designed as off-the-shelf solutions for use in different patients. However, both approaches have their challenges. The manufacturing process for autologous CAR-T cells is complex and costly, as each patient’s cells must be individually processed. Allogeneic CAR-T cells, on the other hand, currently do not have the same safety profile, necessitating further research to address these issues.

 

^{*All products are for Research Use Only (RUO).}